
## **Caroline Nothdurfter**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/12069788/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Differential effects of the translocator protein 18ÂkDa (TSPO) ligand etifoxine and the benzodiazepine alprazolam on startle response to predictable threat in a NPU-threat task after acute and short-term treatment. Psychopharmacology, 2022, , 1.	3.1	0
2	A novel dual mode-of-action anti-hyperalgesic compound in rats which is neuroprotective and promotes neuroregeneration. European Journal of Pharmacology, 2022, 923, 174935.	3.5	4
3	Dissociation of endocrine responses to the Trier Social Stress Test in Virtual Reality (VR-TSST) by the benzodiazepine alprazolam and the translocator protein 18ÂkDa (TSPO) ligand etifoxine. Psychoneuroendocrinology, 2021, 124, 105100.	2.7	5
4	The cytokine ILâ€17A as a marker of treatment resistance in major depressive disorder?. European Journal of Neuroscience, 2021, 53, 172-182.	2.6	24
5	Computer-Assisted Avatar-Based Treatment for Dysfunctional Beliefs in Depressive Inpatients: A Pilot Study. Frontiers in Psychiatry, 2021, 12, 608997.	2.6	5
6	Major Depressive Disorder is Associated with Impaired Mitochondrial Function in Skin Fibroblasts. Cells, 2020, 9, 884.	4.1	28
7	Association of Chemokine (C-C Motif) Receptor 5 and Ligand 5 with Recovery from Major Depressive Disorder and Related Neurocognitive Impairment. NeuroImmunoModulation, 2020, 27, 152-162.	1.8	13
8	CRISPR-Cas9 Mediated TSPO Gene Knockout alters Respiration and Cellular Metabolism in Human Primary Microglia Cells. International Journal of Molecular Sciences, 2019, 20, 3359.	4.1	45
9	The Role of Chemokines in the Pathophysiology of Major Depressive Disorder. International Journal of Molecular Sciences, 2019, 20, 2283.	4.1	94
10	Differential effects of TSPO ligands on mitochondrial function in mouse microglia cells. Psychoneuroendocrinology, 2019, 106, 65-76.	2.7	57
11	Effects of genetic variants in the TSPO gene on protein structure and stability. PLoS ONE, 2018, 13, e0195627.	2.5	19
12	Macrophage-Derived Chemokine: A Putative Marker of Pharmacological Therapy Response in Major Depression?. NeuroImmunoModulation, 2017, 24, 106-112.	1.8	17
13	Translocator protein (18ÂkDa) (TSPO) is expressed in reactive retinal microglia and modulates microglial inflammation and phagocytosis. Journal of Neuroinflammation, 2014, 11, 3.	7.2	177
14	Effects of escitalopram/quetiapine combination therapy versus escitalopram monotherapy on hypothalamic–pituitary–adrenal-axis activity in relation to antidepressant effectiveness. Journal of Psychiatric Research, 2014, 52, 15-20.	3.1	15
15	The role of allopregnanolone in depression and anxiety. Progress in Neurobiology, 2014, 113, 79-87.	5.7	227
16	Impact on cortisol and antidepressant efficacy of quetiapine and escitalopram in depression. Psychoneuroendocrinology, 2014, 39, 141-151.	2.7	35
17	The influence of Hatha yoga as an add-on treatment in major depression on hypothalamic–pituitary–adrenal-axis activity: A randomized trial. Journal of Psychiatric Research, 2014, 53, 76-83.	3.1	45
18	Lipid raft integrity affects GABAA receptor, but not NMDA receptor modulation by psychopharmacological compounds. International Journal of Neuropsychopharmacology, 2013, 16, 1361-1371.	2.1	29

## CAROLINE NOTHDURFTER

#	Article	IF	CITATIONS
19	Recent Developments in Potential Anxiolytic Agents Targeting GABAA/BzR Complex or the Translocator Protein (18kDa) (TSPO). Current Topics in Medicinal Chemistry, 2012, 12, 360-370.	2.1	21
20	Translocator protein (18ÂkDa) (TSPO) as a therapeutic target for anxiety and neurologic disorders. European Archives of Psychiatry and Clinical Neuroscience, 2012, 262, 107-112.	3.2	49
21	Lack of association of the 5â€HT <sub>3A</sub> receptor with schizophrenia. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2012, 159B, 310-315.	1.7	8
22	The influence of anaesthetic medication on safety, tolerability and clinical effectiveness of electroconvulsive therapy. World Journal of Biological Psychiatry, 2010, 11, 447-456.	2.6	16
23	Impact of Lipid Raft Integrity on 5-HT3 Receptor Function and its Modulation by Antidepressants. Neuropsychopharmacology, 2010, 35, 1510-1519.	5.4	36
24	Identification of a Domain which Affects Kinetics and Antagonistic Potency of Clozapine at 5-HT3 Receptors. PLoS ONE, 2009, 4, e6715.	2.5	12
25	Lithium but not carbamazepine augments antidepressant efficacy of mirtazapine in unipolar depression: An open-label study. World Journal of Biological Psychiatry, 2009, 10, 390-399.	2.6	19
26	Translocator Protein (18 kD) as Target for Anxiolytics Without Benzodiazepine-Like Side Effects. Science, 2009, 325, 490-493.	12.6	299
27	Neuroactive Steroids as Endogenous Modulators of Anxiety. Current Pharmaceutical Design, 2008, 14, 3525-3533.	1.9	52
28	Pitfalls in isolating lipid rafts. Nature Reviews Neuroscience, 2007, 8, 567-567.	10.2	6
29	The influence of concomitant antidepressant medication on safety, tolerability and clinical effectiveness of electroconvulsive therapy. World Journal of Biological Psychiatry, 2006, 7, 82-90.	2.6	41
30	The influence of concomitant neuroleptic medication on safety, tolerability and clinical effectiveness of electroconvulsive therapy. World Journal of Biological Psychiatry, 2006, 7, 162-170.	2.6	46
31	Induced neural progenitor cells and iPS-neurons from major depressive disorder patients show altered bioenergetics and electrophysiological properties. Molecular Psychiatry, 0, , .	7.9	5